Daunorubicin and idarubicin provided similar benefits when combined with cytarabine for most patients with acute myeloid leukemia.
Obstetrician-gynecologists play key roles, but should consider referral to a genetic specialist as necessary.
Treatment was effective for 70% of hemorrhages associated with apixaban or rivaroxaban.
Physician assistant and clinical preceptor in gynecologic oncology Megan Tetlow has some dos and don'ts for PA and NP students on rotations, in the In Practice blog.
From 1990 through 2013, the percentage of patients with non–small-cell lung cancer who never smoked rose from 8.0% to 14.9%.
Palbociclib demonstrated activity in early-stage disease resistant to endocrine therapy, but prolonged exposure may be required.
Symptom relief was more rapid with ruxolitinib versus best available therapy, but adverse effects were more frequent.
Substituting obinutuzumab for rituximab during induction chemotherapy did not improve outcomes.
Patients show an elevated risk for myocardial infarction and ischemic stroke 6 months after cancer diagnosis.
Response rates were higher with decitabine, especially in higher-risk patients.
Prof. Dr. med. Florian Otto
Tumor- und Brustzentrum ZeTuP, St. Gallen
E-Mail: E-Mail anzeigen
Immuntherapie ist in aller Munde. Checkpoint-Inhibitoren werden bei praktisch allen onkologischen Erkrankungen erprobt und erweisen sich häufig als wirksam – zumindest für eine gewisse Zeit. Aber wie entwickelt sich eine Resistenz? Dieser Frage sind Zaretsky und Kollegen im Kontext von vier Melanompatienten unter Pembrolizumab-Therapie nachgegangen und haben Defekte im Interferon-Signalweg sowie der Antigenpräsentation in den Tumorzellen gefunden.
The objective response rate was 33%, and the median duration of response was 28 months.
Pembrolizumab induced frequent and durable responses with manageable toxicity.
In a randomized trial, platelet transfusion was associated with worse outcomes in patients with spontaneous ICH who were on antiplatelet therapy.
Duration of response justifies further study.
Long-term randomized-trial results show a dramatic improvement in survival for patients with low-grade glioma treated initially with radiation plus chemotherapy versus radiation alone.
Adding the oral proteasome inhibitor ixazomib to lenalidomide plus dexamethasone improved outcomes, even in high-risk subgroups.
Survival was similar with chemoradiotherapy or chemotherapy alone in patients without progression after induction chemotherapy.
Patients had a threefold higher cumulative incidence of major cardiac events than did a control population without cancer.
Ten-year survival was similar with ABVD or BEACOPP, but BEACOPP was associated with a high rate of late second malignancies.
The trial did not meet its primary endpoint of noninferiority for gefitinib in terms of progression-free survival.